# Ozempic Teeth: What Has Actually Been Measured, and What Has Not | This GLP

Dry mouth is the oral effect most consistently reported with semaglutide, alongside taste change, reflux and caries. No study pools a prevalence, and no trial has counted cavities.

Publisher: This GLP Editorial Team
Canonical: https://thisglp.com/research/ozempic-teeth
Updated: 2026-09-17
Published: 2026-09-17

[← Research](https://thisglp.com/research)

Safety

# Ozempic Teeth: What Has Actually Been Measured, and What Has Not

Dry mouth, altered taste, reflux and more cavities are all reported. No study reports a rate, and the route to damaged teeth runs through dryness and acid rather than the drug itself.

[This GLP Editorial Team](https://thisglp.com/about)September 20267 min read

What the literature contains · dry mouth · taste change · reflux · more cavities · a measured rate · Reported is not the same as common.

**Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms).

## Key takeaways

-   Dry mouth is the oral effect most consistently reported with semaglutide, across reviews and adverse-event reporting systems.
-   Altered taste, reflux, dry throat, bad breath and more dental caries also appear in the literature.
-   No study reports a prevalence. Three narrative reviews describe these effects; none pools a rate, and no randomized trial has counted cavities.
-   The likely route to tooth damage is indirect — dry mouth and reflux — which is what makes it something a dentist can act on.

“Ozempic teeth” is not a diagnosis, and no trial has measured it. What exists is a set of oral effects reported consistently enough to take seriously, with no study yet attaching a rate to any of them. That is a different kind of gap from the one in [the pooled serious adverse events](https://thisglp.com/research/which-glp1-has-the-worst-side-effects), where the trials counted and the total was small.

## What is actually reported

A narrative review of semaglutide and the mouth drew on clinical trials, pharmacovigilance analyses, observational studies, case reports and laboratory work [\[1\]](https://thisglp.com/research/ozempic-teeth#ref-1). Dry mouth — xerostomia or hyposalivation — is the effect it found reported most consistently. The review states that rates vary across studies and does not combine them. That is the same unpooled shape this site described in [two meta-analyses built on the same six trials](https://thisglp.com/research/glp1-two-meta-analyses-same-six-trials).

Alongside dry mouth it lists altered taste, dry throat, reduced sensation in the mouth, bad breath, frothy saliva and more dental caries. Reporting systems show signals for dry mouth and taste change, and case series confirm reduced saliva, though a reporting signal measures what was reported rather than how often it happens.

A second review, covering the oral and maxillofacial region specifically, adds reflux, nasopharyngitis and taste disturbance to the same list [\[2\]](https://thisglp.com/research/ozempic-teeth#ref-2). Its authors ask clinicians to keep these drugs in the differential diagnosis, because the effects overlap with conditions that have entirely different causes.

## Why teeth, when the drug does not touch them

The reported route from a GLP-1 drug to dental damage is indirect.
| What happens | Why it follows | What it does to teeth |
| --- | --- | --- |
| Less saliva | Nausea, eating and drinking less, slower gastric emptying | Saliva buffers acid and clears sugar; less of it raises caries risk |
| Reflux | Delayed gastric emptying pushes acid upward | Acid reaches enamel directly |
| Altered taste | Reported directly with the drug | Can change what and how often someone eats |

The reported route from a GLP-1 drug to dental damage is indirect. Narrative reviews of oral adverse effects

The first review is careful about the order of events: dry mouth often arrives secondary to gastrointestinal symptoms rather than from the drug acting on salivary glands directly. That matters for what a reader can do about it. A mouth that is dry because someone is drinking less is a different problem from a gland that has stopped working.

Indirect is the useful finding, not a reassurance

None of this says the risk is imaginary. It says the mechanism runs through dryness and acid, both of which a dentist can see and both of which have standard management. It also means the effect should track how strong the gastrointestinal symptoms are — which is the same pattern this site described in [what titration does to the nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1).

## One study points the other way

A 2026 review of the oral microbiome in obstructive sleep apnea argues that these drugs introduce competing influences [\[3\]](https://thisglp.com/research/ozempic-teeth#ref-3). Untreated sleep apnea drives mouth breathing, salivary drying and acid challenge on its own. So a drug that reduces apnea severity may improve the oral environment, even while its salivary effects push the other way.

That review is a synthesis of mechanisms rather than a measurement of outcomes, so it does not settle the question. It does mean a blanket claim in either direction is unsupported. The apnea evidence itself is in [what happened across every apnea subgroup](https://thisglp.com/research/apnea-improved-across-every-subgroup).

## What nobody has measured

No randomized trial has counted cavities in people taking these drugs. No study reports what share of users develop dry mouth, or how long it lasts, or whether it resolves when the dose stops climbing. Those are not gaps this site can close by reading harder; they are measurements nobody has taken.

One of the reviews also records that these drugs promote a gaunt facial appearance, which is the observation behind a much larger volume of searching than the dental one. What has actually been measured about facial volume, and what is only proposed, is set out in [how to avoid Ozempic face](https://thisglp.com/research/how-to-avoid-ozempic-face).

For a reader currently on one of these drugs, the practical implication is narrow. Dryness and reflux are both worth raising at a dental appointment, as medication effects rather than as unrelated symptoms. What a seller will tell you about any of this is covered in [whether disclosure is a trait of the seller](https://thisglp.com/research/is-seller-disclosure-a-trait).

## Frequently asked

Does Ozempic damage your teeth?

No trial has counted cavities in people taking it. Reviews report more dental caries alongside dry mouth and reflux, but no study reports a rate, so the size of the risk is unmeasured.

Why would a GLP-1 drug affect teeth at all?

Indirectly. Nausea and reduced intake lower saliva, which normally buffers acid and clears sugar, and delayed gastric emptying can push acid up as reflux. Both damage enamel without the drug touching it.

How common is dry mouth on semaglutide?

Not established. It is the oral effect most consistently reported, and adverse-event systems show a signal for it, but the review that gathered the literature states rates vary across studies and does not pool them.

Does it get better?

Nobody has measured that. No study reports how long these effects last or whether they resolve once the dose stops escalating.

What should I do about it?

Raise dryness and reflux at a dental appointment and say they began with the medication, since both have standard management and both overlap with conditions that have other causes.

## Sources

1.  \[1\] Al-Zawawi AS (2024). Oral Adverse Effects of Semaglutide Therapy: A Narrative Review Journal of International Society of Preventive and Community Dentistry. [PMID 42730115](https://pubmed.ncbi.nlm.nih.gov/42730115/)
2.  \[2\] Brooks JK, Sultan AS (2026). Potential oral and maxillofacial adverse events associated with glucagon-like peptide-1 receptor agonist administration: a narrative review Quintessence International. [PMID 42334501](https://pubmed.ncbi.nlm.nih.gov/42334501/)
3.  \[3\] Comisi JC (2026). Obstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy, and the oral microbiome: competing biological influences and implications for oral health monitoring Clinical Oral Investigations. [PMID 42734711](https://pubmed.ncbi.nlm.nih.gov/42734711/)

## More in Safety

-   [
    
    Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option
    
    ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks
    
    ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic)
-   [
    
    1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg
    
    ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call
    
    ](https://thisglp.com/research/does-ozempic-cause-diarrhea)
-   [
    
    Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms
    
    ### Does Ozempic Cause Dizziness? What to Check First
    
    ](https://thisglp.com/research/does-ozempic-cause-dizziness)